Srpt nasdaq

Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases. We’re ushering in a new era of drug development, with the goal of shortening the time from lab to patient, building the world’s largest gene therapy manufacturing capacity ....

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript November 1, 2023 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.46, expectations were $-1.63.View real-time SRPT stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Richard Barry, who is a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), bought 50,000 shares of the company at $78.81 per share. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s CEO Douglas Ingram also bought 25,225 shares of the company earlier this month at $79.36 per share.

Did you know?

Sarepta SRPT announced that an FDA advisory committee narrowly recommended approving the company’s biologics license application ("BLA") seeking accelerated approval for SRP-9001 to treat ...View the latest Sarepta Therapeutics Inc. (SRPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

SRPT SRPT AFTER HOURS QUOTE SRPT LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...The latest price target for Sarepta Therapeutics ( NASDAQ: SRPT) was reported by RBC Capital on Tuesday, November 21, 2023. The analyst firm set a price target for 148.00 …Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analyst estimates of $285.33 million.Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include ...

Sarepta Therapeutics Price Performance. Shares of NASDAQ:SRPT opened at $81.28 on Friday. The company has a market cap of $7.60 billion, a price-to-earnings ratio of -10.38 and a beta of 0.96.Current Trading Halts. Nov 30, 2023. Halt times displayed are Eastern Time (ET). updating.... Pause Threshold Price. If a security is subject to a Trading Pause, the Pause Threshold Price field will contain the reference threshold price that deviates 10% from a print on the Consolidated Tape that is last sale eligible as compared to every print ... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Srpt nasdaq. Possible cause: Not clear srpt nasdaq.

Nov 21, 2023 · Find the latest news headlines from Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) at Nasdaq.com. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call ...

$176.65 UNCH TSLA Tesla, Inc. Common Stock $220.20 +0.24 +0.11% NVDA NVIDIA Corporation Common Stock $450.47 +0.42 +0.09% MSFT Microsoft Corporation Common Stock $352.60 -0.20 -0.06% Investors may... Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shareholders (or potential shareholders) will be happy to see that the Independent Director, Richard Barry, recently bought a whopping US$3.9m worth of stock, at a price of US$78.81.While that only increased their holding size by 1.7%, it is still a big swing by our standards. View our …

my car was vandalized will insurance cover it Transcript : Sarepta Therapeutics, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 09:00 AM. Nov. 09. CI. Sarepta Therapeutics Insider Bought Shares Worth $2,001,800, According to a Recent SEC Filing. Nov. 06. MT. Sarepta Therapeutics Insider Bought Shares Worth $3,940,500, According to a Recent SEC Filing. o'reilly stocksshort term medical insurance washington state Cantor Fitzgerald analyst Kristen Kluska downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Neutral with a price target of $40.00 (from $166.00). For an analyst ratings summary and... j.p. morgan equity income etf View live Sarepta Therapeutics, Inc. chart to track its stock's price action. Find market predictions, SRPT financials and market news. stocktwits aaplcyro cellvgsix Sarepta Therapeutics Q3 Earnings Summary. RTTNews. Nov. 1, 2023, 04:19 PM. (RTTNews) - Below are the earnings highlights for Sarepta Therapeutics (SRPT): Earnings: -$40.94 million in Q3 vs. -$257. ...Nov 29, 2023 · Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analyst estimates of $285.33 million. recent ponzi schemesrival incvelo stock priceinvest with henry reviews Sarepta Therapeutics (NASDAQ:SRPT) Q3 results:Revenues: $143.9M (+45.4%); product sales: $121.4M (+22.6%); collaboration revenue: $22.5M (primarily from...